ORGS Stock Overview
A biotech company, focuses on cell and gene therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Orgenesis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$10.80 |
| 52 Week Low | US$0.87 |
| Beta | 1.1 |
| 1 Month Change | 82.61% |
| 3 Month Change | -45.17% |
| 1 Year Change | -51.83% |
| 3 Year Change | -91.89% |
| 5 Year Change | -95.35% |
| Change since IPO | 456.97% |
Recent News & Updates
Recent updates
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%
Mar 04
Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M
Aug 16Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study
May 06Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration
Apr 30Shareholder Returns
| ORGS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -26.1% | 0.2% | -0.2% |
| 1Y | -51.8% | -4.7% | 25.8% |
Return vs Industry: ORGS underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: ORGS underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| ORGS volatility | |
|---|---|
| ORGS Average Weekly Movement | 29.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORGS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ORGS's weekly volatility has increased from 24% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 146 | Vered Caplan | orgenesis.com |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Orgenesis Inc. Fundamentals Summary
| ORGS fundamental statistics | |
|---|---|
| Market cap | US$10.86m |
| Earnings (TTM) | -US$34.41m |
| Revenue (TTM) | US$899.00k |
12.1x
P/S Ratio-0.3x
P/E RatioIs ORGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORGS income statement (TTM) | |
|---|---|
| Revenue | US$899.00k |
| Cost of Revenue | US$1.78m |
| Gross Profit | -US$878.00k |
| Other Expenses | US$33.53m |
| Earnings | -US$34.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.66 |
| Gross Margin | -97.66% |
| Net Profit Margin | -3,827.81% |
| Debt/Equity Ratio | -63.2% |
How did ORGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:11 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orgenesis Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Carol Werther | Dawson James Securities |